Aurobindo Pharma Limited has informed the Exchange about General Updates

Regulatory product approvalBusiness Updates View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1159.00

prior close

₹1164.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.2%-0.2% vs market

Pharmaceuticals peers, median of 151sector+0.3%-0.3% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-1.3

15m

-1.1

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.2-0.2+0.3-0.3

Next day

+2.8+0.2+2.6+0.8+2.0

+2.0-0.1+2.1+0.2+1.8

-1.5-0.2-1.2+0.0-1.5

-1.4-0.3-1.1+0.1-1.5

-2.5-0.6-1.9-0.2-2.3

-1.8-0.8-1.1+0.3-2.1

15d

-3.7-0.4-3.3+0.5-4.1

-5.8-2.8-3.0-1.4-4.4

-10.7-3.0-7.7-2.8-7.9

-5.5-2.5-3.1-3.1-2.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has received marketing authorization from the European Commission for Dazublys™, its trastuzumab biosimilar (used in breast cancer treatment). This follows a positive opinion from the EMA's CHMP in April 2025. Dazublys™ is CuraTeQ's third biosimilar approved by the EMA this year, following Dyrupeg™ (April 2025) and Zefylti™ (February 2025), and its fourth overall approval in the EU region alongside Bevqolva™, which was approved by the UK's MHRA in December 2024.

Likely market impact

This approval expands Aurobindo's biosimilar footprint in the lucrative European market. A steady stream of biosimilar approvals signals strong R&D execution and could contribute meaningfully to long-term revenue growth, though near-term financial impact is not quantified in this filing.